Physician
Internal Medicine
Dr. Thomas J. Podsadecki, MD
Thomas Podsadecki is an expert in the field of Internal Medicine. Thomas Podsadecki is a published doctor as well. He has 21 publications published. The latest was: Effects of organizational change in the medical intensive care unit of a teaching hospital: a comparison of 'open' and 'closed' formats.
Publications
- Evaluation of Drug-Drug Interactions Between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtr...
- Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subje...
- Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Health...
- Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir.
- Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, a...
- ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
- ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV.
- ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV G...
- Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antire...
- Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.
- "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
- Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
- Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
- A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
- Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.
- A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
- Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
- Effects of organizational change in the medical intensive care unit of a teaching hospital: a comparison of 'open' and 'closed' formats.
- Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.
- Journal pricing issues: an economic perspective.
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
University of Chicago
Helpful Reviews
Similar Doctors
|
Dr. Muhammad A. Shahzad, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin E. Hunt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay Hildebrand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark K. Kosinski, DO |
|
|
Dr. Marlon D. Garcia, MD |
|
|
Dr. Bushra Z. Osmani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Courtney A. Noble, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dhara S. Naik, DO |
|
|
Dr. Adel Nada, MD |
|
|
Dr. Byung Ho H. Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Renslow Sherer, MD
This Doctor is OpenDoctor Recommended.
|